CohenJPFelixAERiggsK. Barriers to market uptake of biosimilars in the US: generics and biosimilars initiative. GaBI J. 2014;3(3):108–115.
2.
SinghSCBagnatoKM. The economic implications of biosimilars. Am J Manag Care. 2015;21(16 suppl):s331–s340.
3.
BlackstoneEAJosephPF. The economics of biosimilars. Am Health Drug Benefits. 2013;6(8):469–478.
4.
GrabowskiHGKyleMMortimerR. Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act. Health Aff (Millwood). 2011;30(11):2157–2166.
5.
Farfan-portetMIGerkensSLepage-NefkensI. Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?Eur J Health Econ. 2014;15(3):223–228.
